⚠ Fourteen Named Rivals, and Two of Them Are EnormousHigh threat
Intuitive Surgical (ISRG) — threat to the moat
Neither Medtronic nor Johnson & Johnson needs robotics to pay for itself in year one.
Intuitive's competition disclosure names fourteen companies that have introduced robotic products or stated an intent to enter: Beijing Surgerii Robotics, CMR Surgical, Distalmotion, Harbin Sizhe Rui, Johnson & Johnson, Karl Storz, Medicaroid, Medtronic, meerecompany, Noah Medical, Shandong Weigao, Shanghai Microport Medbot, Shenzhen Edge Medical and SS Innovations1.
Two of those names matter far more than the other twelve. The 10-K explains why: "as we add new robotically controlled products (e.g., da Vinci stapling and da Vinci energy products) that compete with product offerings traditionally within the domains of open surgery and/or conventional MIS, we face greater competition from larger and well-established companies, such as Johnson & Johnson and Medtronic plc"2.
That is the important structural point. Intuitive's growth strategy has been to take more of each case — staplers, energy devices, vessel sealers — which are exactly the products Johnson & Johnson's Ethicon and Medtronic's surgical business have sold for decades. Expanding into that ground brings Intuitive into competition with companies that already have the surgeon relationships, the manufacturing scale and the distribution.
Neither has yet displaced meaningful volume, and the reason is the one on this page: clearances, evidence and trained surgeons take years. But neither needs to win quickly. Both can fund a robotics programme out of businesses that are already profitable, and both are in the same hospitals every week.
Their system counts will lag for years and are not the tell. Intuitive's pricing is: average selling price was approximately $1.60 million in 2025 against $1.50 million in 20243. A rising ASP means nobody is competing on price yet. The first sustained decline would mean somebody is.
- ReportedIntuitive's competition disclosure names fourteen companies that have introduced robotic products or stated an intent to enter: Beijing Surgerii Robotics, CMR Surgical, Distalmotion, Harbin Sizhe Rui, Johnson & Johnson, Karl Storz,...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedThe 10-K explains why: "as we add new robotically controlled products (e.g., da Vinci stapling and da Vinci energy products) that compete with product offerings traditionally within the domains of open surgery and/or conventional MIS, we...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedIt is Intuitive's pricing: average selling price was approximately $1.60 million in 2025 against $1.50 million in 2024.Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗